Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience

Background: Lapelga(®) was approved by Health Canada as a pegfilgrastim biosimilar in 2019 and remains the most commonly used biosimilar in Ontario and is fully reimbursed under the Ontario Drug Benefit program in this category. We explored the efficacy and tolerability of Lapelga(®) in a retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Fahad, Black, Morgan, Charlton, Alaina, Younus, Jawaid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047890/
https://www.ncbi.nlm.nih.gov/pubmed/36975457
http://dx.doi.org/10.3390/curroncol30030244
_version_ 1785014040298258432
author Khan, Fahad
Black, Morgan
Charlton, Alaina
Younus, Jawaid
author_facet Khan, Fahad
Black, Morgan
Charlton, Alaina
Younus, Jawaid
author_sort Khan, Fahad
collection PubMed
description Background: Lapelga(®) was approved by Health Canada as a pegfilgrastim biosimilar in 2019 and remains the most commonly used biosimilar in Ontario and is fully reimbursed under the Ontario Drug Benefit program in this category. We explored the efficacy and tolerability of Lapelga(®) in a retrospective analysis of patients with early breast cancer who underwent adjuvant chemotherapy supported with Lapelga(®) as a primary prophylaxis. Methods: Adult patients with early breast cancer treated with adjuvant chemotherapy at the London Regional Cancer Program in London, ON, Canada between May 2019 and June 2022 were included. All of these patients were supported with Lapelga(®) as the primary prophylaxis. Patients’ age, tumour, and nodal status, their type of chemotherapy, co-morbid conditions, and incidence of febrile neutropenia (FN) and its related details as well as any reported side effects to Lapelga(®) were collected. Results: A total of 201 patients were included in this review with majority (78%) of patients under 65 years of age. One third of patients were treated with the adriamycin and cyclophosphamide (AC)-Paclitaxel dose dense chemotherapy and a quarter of patients with either a docetaxel and cyclophosphamide (TC) combination or an AC-dose dense with Paclitaxel weekly, and 10% or less patients had FEC-D (5-fluorouracil, epirubicin, and cyclophosphamide) and AC chemotherapy. FN incidence was only 3.48% in this review (7/201 patients). Patients with FN were admitted to hospital and recovered completely with no mortality reported. No cases of a switch to a different granulocyte colony growth factor were seen. The most frequent side effects from Lapelga(®) included musculoskeletal pain, fever, and headache. However, the majority of patients (88.6%; 178/201) did not have any reported side effects specifically assigned to Lapelga(®). Conclusions: In this single centre retrospective study, early breast cancer patients (n = 201) treated with adjuvant chemotherapy supported with primary prophylaxis with Lapelga(®) had a low incidence of FN (3.48%). This supports Lapelga(®) being an effective strategy as the primary prophylaxis when used with common chemotherapy regimens in the real-world setting.
format Online
Article
Text
id pubmed-10047890
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100478902023-03-29 Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience Khan, Fahad Black, Morgan Charlton, Alaina Younus, Jawaid Curr Oncol Communication Background: Lapelga(®) was approved by Health Canada as a pegfilgrastim biosimilar in 2019 and remains the most commonly used biosimilar in Ontario and is fully reimbursed under the Ontario Drug Benefit program in this category. We explored the efficacy and tolerability of Lapelga(®) in a retrospective analysis of patients with early breast cancer who underwent adjuvant chemotherapy supported with Lapelga(®) as a primary prophylaxis. Methods: Adult patients with early breast cancer treated with adjuvant chemotherapy at the London Regional Cancer Program in London, ON, Canada between May 2019 and June 2022 were included. All of these patients were supported with Lapelga(®) as the primary prophylaxis. Patients’ age, tumour, and nodal status, their type of chemotherapy, co-morbid conditions, and incidence of febrile neutropenia (FN) and its related details as well as any reported side effects to Lapelga(®) were collected. Results: A total of 201 patients were included in this review with majority (78%) of patients under 65 years of age. One third of patients were treated with the adriamycin and cyclophosphamide (AC)-Paclitaxel dose dense chemotherapy and a quarter of patients with either a docetaxel and cyclophosphamide (TC) combination or an AC-dose dense with Paclitaxel weekly, and 10% or less patients had FEC-D (5-fluorouracil, epirubicin, and cyclophosphamide) and AC chemotherapy. FN incidence was only 3.48% in this review (7/201 patients). Patients with FN were admitted to hospital and recovered completely with no mortality reported. No cases of a switch to a different granulocyte colony growth factor were seen. The most frequent side effects from Lapelga(®) included musculoskeletal pain, fever, and headache. However, the majority of patients (88.6%; 178/201) did not have any reported side effects specifically assigned to Lapelga(®). Conclusions: In this single centre retrospective study, early breast cancer patients (n = 201) treated with adjuvant chemotherapy supported with primary prophylaxis with Lapelga(®) had a low incidence of FN (3.48%). This supports Lapelga(®) being an effective strategy as the primary prophylaxis when used with common chemotherapy regimens in the real-world setting. MDPI 2023-03-09 /pmc/articles/PMC10047890/ /pubmed/36975457 http://dx.doi.org/10.3390/curroncol30030244 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Khan, Fahad
Black, Morgan
Charlton, Alaina
Younus, Jawaid
Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience
title Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience
title_full Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience
title_fullStr Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience
title_full_unstemmed Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience
title_short Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience
title_sort primary prophylaxis lapelga(®) in early breast cancer: a real-world experience
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047890/
https://www.ncbi.nlm.nih.gov/pubmed/36975457
http://dx.doi.org/10.3390/curroncol30030244
work_keys_str_mv AT khanfahad primaryprophylaxislapelgainearlybreastcancerarealworldexperience
AT blackmorgan primaryprophylaxislapelgainearlybreastcancerarealworldexperience
AT charltonalaina primaryprophylaxislapelgainearlybreastcancerarealworldexperience
AT younusjawaid primaryprophylaxislapelgainearlybreastcancerarealworldexperience